
Balancing Treatment Sequencing and Patient Needs in Relapsed/Refractory Multiple Myeloma
Teams Catalyst and Compass continue the debate on sequencing treatment at relapse in relapsed/refractory multiple myeloma, exploring how to balance preserving future options with selecting the most appropriate therapy for the current disease state.
Episodes in this series

Teams Catalyst and Compass continue the debate on sequencing treatment at relapse in relapsed/refractory multiple myeloma, exploring how to balance preserving future options with selecting the most appropriate therapy for the current disease state. Faculty discuss whether, when two treatments are considered similarly effective, clinicians should account for how one option may affect subsequent therapies, particularly CAR T-cell therapy and bispecific antibodies. The discussion highlights the importance of considering T-cell fitness, prior treatment exposure, disease biology, patient comorbidities, treatment burden, and supportive care requirements. Faculty emphasize that the optimal treatment for the disease may not always be the best fit for the individual patient, particularly when access, travel, and the need for ongoing supportive care are considered. The panel also contrasts community and academic practice settings, noting that community-based patients may have fewer treatment opportunities and that bridging or holding therapy can help control disease while patients await CAR T-cell therapy. Overall, treatment sequencing remains an important consideration, but decisions should prioritize current disease control and individual patient needs.
Related to this article








